Sign In
Buy BIVI
$1.65
-0.0500 (-2.94%)
At Close: Jun 03, 2026
BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year
12:28pm, Friday, 14'th Oct 2022
BioVie recently presented one of the best cognition improvements ever reported in an open label study in Alzheimer's disease. Further reporting and biomarkers confirmed those improvements, making BioV
BioVie (BIVI) Stock Pops on Positive Alzheimer's Trial Results
11:30am, Wednesday, 07'th Sep 2022
In a fresh press release from this morning, BioVie (NASDAQ: BIVI ) disclosed top-line results from a Phase 2 clinical trial for its Alzheimer's disease treatment, NE3107. The results were largely posi
BioVie shares soar 19% premarket after company announces positive results from Phase 2 trial of Alzheimer's treatment
06:20am, Wednesday, 07'th Sep 2022
BioVie Inc. shares BIVI, +22.42% rose 19% in premarket trade Wednesday, after the biotech announced positive results from a Phase 2 trial of its Alzheimer's Disease treatment NE3107. Moving away from
BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent
11:24am, Tuesday, 06'th Sep 2022
Earlier June coverage of BioVie showed the company's potential in Alzheimer's and Parkinson's. Since that coverage, the company seems to have been set up for success.
Why Did BioVie Shares Jump 21% Today?
04:49pm, Tuesday, 26'th Oct 2021
The FDA has signed off BioVie Inc's (NASDAQ: BIVI) Phase 2 study assessing NE3107's potential pro-motoric impact in Parkinson's disease patients. The NM201 study is a double-blind, placebo-controll
BioVie to Present at Cantor Virtual Global Healthcare Conference
08:00am, Wednesday, 22'nd Sep 2021
SANTA MONICA, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment
BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit
04:01pm, Wednesday, 15'th Sep 2021
SANTA MONICA, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment
BioVie Stock Plunges On $20M Capital Raise Via Equity At Deep Discount Of 38%
07:04am, Monday, 09'th Aug 2021
BioVie Inc (NASDAQ: BIVI) priced its underwritten public offering of 2.5 million shares at $8.00 per share for gross proceeds of $20 million. The offer price represents a steep discount of 37.7% fr
BioVie Inc. Announces Pricing of Public Offering of Common Stock
09:28pm, Sunday, 08'th Aug 2021
SANTA MONICA, Calif., Aug. 08, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment
BioVie Inc. Announces Proposed Public Offering of Common Stock
05:30pm, Friday, 06'th Aug 2021
SANTA MONICA, Calif., Aug. 06, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment
Pivotal Phase 3 Trial of NE3107 Expected to Commence in Summer 2021 Pivotal Phase 3 Trial of NE3107 Expected to Commence in Summer 2021
BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
08:00am, Friday, 25'th Jun 2021
Chairman Terren Peizer discusses BioVie's late-stage drug pipeline with multiple shots on goal Chairman Terren Peizer discusses BioVie's late-stage drug pipeline with multiple shots on goal
BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
04:05pm, Thursday, 17'th Jun 2021
SANTA MONICA, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"),a clinical-stage company developing innovative drug therapies for the treatment of liver dise
BioVie Hosting Research & Development Day
08:00am, Wednesday, 12'th May 2021
SANTA MONICA, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver dise
Moving Average Crossover Alert: BioVie (BIVI)
06:46am, Wednesday, 12'th May 2021
BioVie (BIVI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
